MIM
PGEN icon

MetLife Investment Management’s Precigen PGEN Stock Holding History

MetLife Investment Management’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
112,919
+29,807
+36% +$129K ﹤0.01% 1771
2026
Q1 		$322K Sell
83,112
-17,021
-17% -$69.8K ﹤0.01% 1964
2025
Q4 		$419K Buy
100,133
+15,816
+19% +$61.2K ﹤0.01% 1876
2025
Q3 		$277K Buy
84,317
+895
+1% +$2.53K ﹤0.01% 2127
2025
Q2 		$118K Buy
83,422
+241
+0.3% +$342 ﹤0.01% 2454
2025
Q1 		$124K Buy
+83,181
New +$131K ﹤0.01% 2421
2024
Q4 		– Sell
-2,631
Closed -$2.49K – 2845
2024
Q3 		$2.49K Sell
2,631
-70,919
-96% -$89.5K ﹤0.01% 2845
2024
Q2 		$116K Buy
73,550
+5,881
+9% +$8.54K ﹤0.01% 2533
2024
Q1 		$98.1K Buy
67,669
+1,505
+2% +$2.16K ﹤0.01% 2549
2023
Q4 		$88.7K Hold
66,164
– – ﹤0.01% 2654
2023
Q3 		$94K Hold
66,164
– – ﹤0.01% 2611
2023
Q2 		$76.1K Hold
66,164
– – ﹤0.01% 2818
2023
Q1 		$70.1K Buy
66,164
+48,698
+279% +$70.2K ﹤0.01% 2674
2022
Q4 		$26.5K Sell
17,466
-36,789
-68% -$63.3K ﹤0.01% 2803
2022
Q3 		$115K Buy
+54,255
New +$114K ﹤0.01% 2614
2022
Q1 		– Sell
-13,296
Closed -$49.3K – 2759
2021
Q4 		$49.3K Sell
13,296
-21,265
-62% -$91.5K ﹤0.01% 2466
2021
Q3 		$172K Buy
34,561
+23,016
+199% +$132K ﹤0.01% 2186
2021
Q2 		$75.3K Sell
11,545
-17,416
-60% -$122K ﹤0.01% 2414
2021
Q1 		$200K Buy
28,961
+10,389
+56% +$87.8K ﹤0.01% 2054
2020
Q4 		$189K Buy
18,572
+3,832
+26% +$24.8K ﹤0.01% 2012
2020
Q3 		$51.6K Sell
14,740
-18,026
-55% -$85.6K ﹤0.01% 2267
2020
Q2 		$164K Hold
32,766
– – ﹤0.01% 2013
2020
Q1 		$111K Hold
32,766
– – ﹤0.01% 2010
2019
Q4 		$180K Hold
32,766
– – ﹤0.01% 2034
2019
Q3 		$187K Hold
32,766
– – ﹤0.01% 1990
2019
Q2 		$251K Sell
32,766
-65,532
-67% -$353K ﹤0.01% 1897
2019
Q1 		$517K Buy
98,298
+65,532
+200% +$454K ﹤0.01% 2025
2018
Q4 		$214K Hold
32,766
– – ﹤0.01% 1874
2018
Q3 		$564K Hold
32,766
– – 0.01% 1460
2018
Q2 		$457K Buy
+32,766
New +$553K 0.01% 1454

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MetLife Investment Management's PGEN Position: Q2 2026 in Review

MetLife Investment Management increased its Precigen (PGEN) stake by 36% in Q2 2026, buying an estimated $129K and bringing the position to 112,919 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

MetLife Investment Management first reported a position in PGEN in Q2 2018 and has held it in 30 quarters since. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • MetLife Investment Management held 112,919 shares of Precigen worth $644K as of Q2 2026.
  • MetLife Investment Management bought 29,807 Precigen shares in Q2 2026, an estimated $129K.
  • Precigen made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1771 holding.
  • MetLife Investment Management first reported a position in Precigen in Q2 2018 and has held it in 30 quarters since.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.